Alzheimer's drug memantine tested on healthy brains – but study halted early

NCT ID NCT02288000

Terminated Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study aimed to see if taking memantine, an Alzheimer's drug, for 15 days would change certain brain and cognitive markers in healthy young men aged 18-30. The goal was to validate a test battery for future Alzheimer's drug development. However, the study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Memantine

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE BATTERY

Contacts and locations

Locations

CHRU de Lille/ Centre d'investigation Clinique

Lille, 59037, France
CIC Marseille

Marseille, France
CIC Toulouse

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.